, Volume 14, Issue 3, pp 175-178
Date: 18 May 2010

Using Telcagepant for the Acute Treatment of Migraine

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content


Connor KM, Shapiro RE, Diener HC, et al.: Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009, 73:970–977.


Of importance.


Migraine is a highly prevalent debilitating headache disorder. Using International Classification of Headache Disorders (ICHD)-II criteria for migraine and probable migraine, between 20% to 24% of the population suffer this disorder. Migraine is also a neurovascular disorder involving the trigeminovascular system [1]. The neuropeptide calcitonin gene-related peptide (CGRP) has a widespread distribution throughout the trigeminovascular system with receptors found on meningeal blood vessels, trigeminal ganglion and afferents, the periaqueductal gray and other brainstem nuclei, the amygdala, and the hypothalamus [2]. CGRP plays a key role in migraine pathophysiology as the main messenger released by the activated trigeminovascular system [3]. This key role is supported by evidence that CGRP infusion in su